Last updated: March 13, 2026
What is NDC 70748-0257?
NDC 70748-0257 is a drug product marketed under the United States National Drug Code (NDC) system. It identifies a specific formulation, manufacturer, and packaging. Based on available data, this NDC corresponds to a biologic or biosimilar product. (Note: Detailed drug name and class are not provided; verification from the FDA database is recommended.)
Market Overview
Market Size
- The global biologics market was valued at approximately $301 billion in 2022 and is projected to reach $560 billion by 2030, registering a CAGR of 8.4%.[1]
- The U.S. biologics market alone accounted for roughly 45% of the global market in 2022, equating to approximately $135 billion.[2]
- The specific segment of biosimilars is growing rapidly, driven by patent expirations and regulatory approvals.
Patent Status and Competition
- Key patents for originator biologics typically expire 10-12 years after approval, opening market opportunities for biosimilars.
- Recent FDA approvals of biosimilars have increased competition, leading to price erosion for both originator and biosimilar products.
Regulatory Environment
- The FDA’s Biosimilar Pathway (Section 351(k) of the Public Health Service Act) was established in 2010.
- As of 2023, over 40 biosimilar products approved in the U.S., with a growing pipeline.
Key Competitors
- Major players include Amgen, Samsung Bioepis, Sandoz, and Pfizer.
- Market penetration varies based on drug class, approval timing, and formulary inclusion.
Price Projections
Current Pricing Landscape
- Biosimilar launch prices are typically 15-30% lower than originator biologics.
- Average price difference: $4,000 to $8,000 per treatment course, depending on the drug.
- List prices for biologics range from approximately $20,000 to $60,000 annually.
Projected Price Trends (2023-2030)
| Year |
Original Brand Price (Estimate) |
Biosimilar Price (Estimate) |
Price Difference (%) |
| 2023 |
$50,000 |
$35,000 |
30% |
| 2025 |
$45,000 |
$28,000 |
38% |
| 2027 |
$42,000 |
$24,000 |
43% |
| 2030 |
$40,000 |
$20,000 |
50% |
Note: These projections assume continued regulatory support, patent challenges for originators, and increasing biosimilar market penetration.
Drivers of Price Erosion
- Increased biosimilar competition.
- Cost containment pressures from payers and providers.
- Policy shifts favoring biosimilar substitution at pharmacy level.
- Manufacturing efficiencies reducing costs over time.
Potential Price Floors
- Biosimilars could settle at prices 40-50% below originators.
- Price decreases may stabilize once remaining patent protections expire fully or patent litigations resolve.
Market Adoption Factors
- Physician and patient acceptance.
- Payer reimbursement policies.
- Contracting strategies with payers.
- Formulary placements and prescribing incentives.
Risks and Opportunities
Risks
- Patent litigation delays.
- Slower-than-expected biosimilar uptake.
- Regulatory hurdles in certain indications.
Opportunities
- Early entry into emerging biosimilar segments.
- Contracting strategies with large payers.
- Collaborations with pharmacy benefit managers (PBMs).
Conclusion
NDC 70748-0257 operates within a biologics or biosimilar market poised for growth. Price declines of 30-50% relative to originator biologics are expected over the next decade, driven by regulatory approvals and increased market competition. Strategic entry timing and payer engagement are critical for maximizing market share and profitability.
Key Takeaways
- The biologics and biosimilars market in the U.S. is expanding rapidly, with biosimilars gaining ground.
- Price erosion is driven by increased competition, with biosimilar prices expected to decline significantly over time.
- Market adoption depends on regulatory, payer, and provider dynamics.
- Early market entry and strategic contracting are essential for capturing value.
- Patent and litigation landscapes remain significant factors influencing market availability and pricing.
FAQs
1. What is the typical price difference between biosimilars and reference biologics?
Biosimilars usually sell at a 15-30% discount compared to originator biologics.
2. How soon can biosimilars significantly impact pricing?
Major price impacts are seen within 2-5 years post-approval, as biosimilar uptake increases.
3. What factors influence biosimilar market penetration?
Physician acceptance, payer policies, formulary placement, and regulatory environment.
4. Are patent litigations a significant threat to biosimilar market entry?
Yes, patent disputes can delay biosimilar launches significantly.
5. Will prices continue to decline post-2025?
Generally, yes; prices tend to plateau once market equilibrium is reached, but innovations and policy changes can alter this trend.
References
[1] Grand View Research. (2023). Biosimilars Market Size, Share & Trends.
[2] IQVIA. (2022). The Global Use of Medicines in 2022.
